Rh‐Incompatible Platelet Transfusion Therapy in Cancer Patients

Publisher Website
Google Scholar
Abstract
The clinical histories of 30 consecutive Rh0D-negative oncology patients transfused with Rh0D-incompatible platelet concentrates were analyzed. No evidence of sensitization to the Rh0D antigen was found whatsoever, in spite of the large numbers of Rh0D-incompatible platelet transfusions given to these patients. Patients with malignant diseases, who are undergoing various forms of antineoplastic therapy, apparently are immunomyelosuppressed, and have severe thrombocytopenia, can safely receive platelets from Rh0D-positive donors without developing evidence of immunization to Rh0D antigens.